You gave the medication time. You followed the dosing plan. Maybe the dose increased several times.

And the result still falls well short of what you and your clinician hoped for.

At this stage, hearing “just be patient” stops being particularly useful.

GLP-1-based weight-management medications produce substantial average weight loss in clinical trials, but an average cannot predict what will happen to one individual. Current 2026 cardiovascular guidance estimates that approximately 10%–15% of trial participants have an inadequate weight-loss response to GLP-1-based therapy.

That does not mean treatment has failed because you did something wrong. It means the treatment strategy needs to be reassessed.

Key takeaways

• GLP-1 non-response is real. Not everyone achieves clinically meaningful weight reduction, even with appropriate treatment.
• Do not declare failure too early. Modern GLP-1-based treatments can require months of titration and continued treatment, and current guidance suggests assessing hyporesponsiveness over roughly three to six months.
• Once response is genuinely inadequate, continuing exactly the same plan indefinitely is not the only option. Current obesity standards recommend treatment intensification.
• Switching medication can be reasonable. But another GLP-1-based drug is not guaranteed to work simply because its average clinical-trial weight loss is greater.
• There is currently no validated genetic, hormonal or microbiome test that reliably predicts an individual’s GLP-1 weight-loss response before treatment. Early response itself remains more clinically useful.

First: what does “my GLP-1 isn’t working” actually mean?

There is no single biological test that labels someone a GLP-1 “non-responder.”

In obesity research, inadequate response is commonly defined using weight loss. A frequently used benchmark is losing less than about 5% of starting body weight after an adequate treatment period, although the appropriate timing depends on the drug, dose escalation and individual circumstances.

Current AHA/ACC/ADA/ASN guidance recommends reassessing GLP-1-related weight-loss hyporesponsiveness within approximately three to six months. This longer window recognizes that newer treatments continue producing weight loss well beyond three months and require gradual dose escalation.

Importantly, inadequate weight loss is not necessarily identical to having no treatment benefit whatsoever. For someone also being treated for type 2 diabetes or another relevant indication, glycemic and other health outcomes may need to be considered before changing therapy solely because the scale response is disappointing.

Before calling it non-response, check five things

1. Have you actually had an adequate treatment trial?

Starter doses are deliberately low. Current Wegovy labeling, for example, begins injectable semaglutide at 0.25 mg weekly and increases it gradually rather than starting at the usual maintenance dose.

If most of your treatment period has been spent titrating, your clinician may decide that the medication has not yet had an adequate trial at a therapeutic dose.

2. Have you reached an appropriate tolerated dose?

Current ADA obesity pharmacotherapy guidance recommends increasing an inadequately effective obesity medication toward the maximum tolerated dose when appropriate before concluding that the medication itself is unsuccessful.

That does not mean everyone needs the maximum labeled dose. Treatment must also remain tolerable, and the appropriate dose is individualized.

If side effects prevent dose escalation, that is itself a reason to reconsider the treatment strategy rather than forcing the dose higher.

3. Has treatment been consistent?

Missed doses, interruptions caused by side effects, injection problems or confusion about a vial concentration can all make the response harder to interpret.

NIDDK recommends following the prescriber’s instructions and reviewing inadequate response with the treating clinician rather than altering a weight-management medication independently.

4. Could other medicines or health factors be affecting the picture?

Some medications can promote weight gain, including certain medications used for depression, psychotic disorders, epilepsy, diabetes and other conditions. That does not mean they should be discontinued: stopping another prescription without medical guidance can be dangerous. But a complete medication review can sometimes identify factors working against the weight-management plan.

Current obesity guidance recommends considering medications, health conditions, tolerability and broader treatment goals when reassessing pharmacotherapy.

5. Do you know exactly what medication you received?

This is particularly relevant to treatment purchased online.

FDA warns that compounded GLP-1 products are not FDA approved and do not receive FDA premarket review for safety, effectiveness or quality. The agency has also identified fraudulent compounded products, dosing errors and illegally marketed products that may contain too much, too little or none of the stated ingredient.

If treatment response is unexpectedly absent, your clinician should be able to confirm the medication, dose, concentration where relevant and dispensing pharmacy.

If the GLP-1 really isn’t working, what happens next?

Current guidance does not recommend simply continuing an ineffective strategy forever.

Possible next step	When it may enter the discussion	Important limitation
Optimize the current dose	Dose remains below the appropriate tolerated treatment dose	More medication is not automatically better
Switch obesity medication	Adequate trial produces insufficient response or tolerability is poor	Another drug is not guaranteed to work
Structured lifestyle treatment	Additional nutrition, activity or behavioral support may improve the overall plan	Should not be framed as “try harder”
Combination pharmacotherapy	Selected patients remain short of treatment goals	Evidence is less established for some combinations; some use may be off-label
Obesity-medicine specialist referral	Response is unusually poor or treatment decisions are becoming complex	Access may be limited
Metabolic/bariatric surgery evaluation	Appropriate candidates remain substantially affected by obesity	Requires separate eligibility and risk-benefit evaluation

The 2026 ADA obesity pharmacotherapy standards specifically recommend escalating the dose where appropriate and, when response remains inadequate at the maximum tolerated dose, considering another obesity medication, intensive lifestyle therapy, combination pharmacotherapy or metabolic/bariatric surgery.

The American College of Physicians similarly recommends discussing benefits, harms, cost, availability, comorbidities, treatment goals, preferences and contraindications when switching weight-management medications because of inadequate response.

Can another GLP-1 work if the first one didn’t?

Potentially—but this needs careful wording.

Different medications do not produce identical average results. In the head-to-head SURMOUNT-5 trial in adults with obesity without diabetes, tirzepatide produced an average 20.2% weight reduction at 72 weeks compared with 13.7% with semaglutide. That establishes a difference in average trial efficacy, not a promise that every individual who responds poorly to semaglutide will respond strongly to tirzepatide.

Some emerging real-world evidence is directly relevant. A 2026 retrospective study included people who switched from therapeutic semaglutide to tirzepatide because of either inadequate response or a weight-loss plateau. Across 61 such switchers, average additional weight loss was 5.3% over six months—but those classified as prior non-responders lost less on average than those who had initially responded and then plateaued.

That study was observational and relatively small, so it should not be interpreted as proof that switching will produce a particular result.

Still, it supports the broader point: response to one medication does not perfectly determine response to another.

A plateau is different from never responding

Someone who lost 15% of their starting weight and then stabilized is not necessarily experiencing treatment failure.

Weight loss eventually slows and commonly reaches a plateau. At that point, the question becomes whether the medication is helping maintain a clinically meaningful reduction—not simply whether the scale continues falling every month.

By contrast, primary inadequate response means that meaningful weight reduction never developed despite an adequate course of treatment.

This distinction matters when considering whether to continue, adjust or switch therapy.

Why doesn’t a GLP-1 work for everyone?

Researchers are actively studying biological differences in GLP-1 response, including genetic, metabolic, hormonal, behavioral and microbiome factors.

But the science is not yet precise enough to look at a new patient and reliably predict, “This drug will not work for you.”

A 2026 review found that no single baseline characteristic reliably predicts response. Genetic associations involving GLP-1 and GIP receptors are being studied, but researchers described current findings as hypothesis-generating rather than ready for individual clinical testing.

That is useful consumer-protection context. Be cautious of expensive tests claiming they can definitively identify your ideal GLP-1 medication based on genetics, hormones or the microbiome unless the claim is supported by validated clinical evidence.

Red flags when a telehealth clinic handles non-response

Poor response is exactly when clinical follow-up becomes valuable.

Be cautious if a program:

• automatically raises the dose without assessing side effects or adherence;
• cannot explain when it considers treatment ineffective;
• has no process for switching treatments;
• tells you weight loss is guaranteed if you simply reach a higher dose;
• encourages taking medication more frequently than prescribed;
• will not identify the dispensing pharmacy;
• describes compounded medication as FDA approved;
• repeatedly renews treatment without meaningful clinical reassessment.

FDA specifically identifies lack of licensed-doctor screening or access to a clinician after receiving medication as telehealth warning signs and says compounded drugs should not be represented as equivalent to FDA-approved products.

Questions to ask your clinician if your GLP-1 isn’t working

A useful review should answer:

• Have I had an adequate trial at an appropriate dose?
• What result are we using to define inadequate response?
• Are there any other health or medication factors worth reviewing?
• Is there any reason to continue the current medication longer?
• Would another weight-management medication be reasonable?
• What evidence supports switching in my situation?
• Would structured nutrition or behavioral support add anything useful?
• Would combination treatment be on-label or off-label?
• At what point would you refer me to an obesity specialist?
• Could metabolic/bariatric surgery ever be relevant to my treatment options?

A clinician should be able to explain not only what happens next, but why.

The practical takeaway

If your GLP-1 genuinely does not produce an adequate response, that is disappointing—but it is clinically useful information.

It means the next conversation should become more specific.

Was the medication adequately dosed? Was it tolerated and taken consistently? Are other factors affecting weight? Is the medication source clear? Would a different treatment offer a better balance of effectiveness, side effects, cost and other health benefits?

Current obesity care provides more than one possible next step.

The aim is not to stay loyal to a medication that is not achieving its purpose. It is to find a treatment strategy whose benefits justify its cost, burden and risks—and to reassess that strategy when the evidence says it is time to change.

Frequently asked questions

What percentage of people do not respond to GLP-1 medications?

Definitions vary, but 2026 cardiovascular guidance estimates that approximately 10%–15% of participants in clinical trials have inadequate weight reduction with GLP-1-based treatment. A separate 2026 review describes non-response—commonly defined as less than 5% total body-weight loss—as affecting roughly 10% in controlled obesity trials, with potentially higher rates in routine clinical practice.

How long should I wait before deciding my GLP-1 isn’t working?

Current guidance suggests assessing GLP-1 weight-loss hyporesponsiveness over approximately three to six months, accounting for dose escalation and treatment consistency. NIDDK also recommends discussing a change when weight loss remains below 5% after 12 weeks on the full dose of a weight-management medication. These are guideposts rather than instructions for stopping treatment without clinician input.

Can I switch from semaglutide to tirzepatide if semaglutide doesn’t work?

A clinician may consider switching obesity medications after inadequate response. Tirzepatide has produced greater average weight loss than semaglutide in a head-to-head trial, and limited observational evidence suggests some patients lose additional weight after switching. However, neither finding guarantees an individual response.

Does no appetite suppression mean my GLP-1 isn’t working?

Not necessarily. Subjective appetite effects vary, and treatment effectiveness should be assessed using the overall clinical response rather than whether a patient can physically “feel” the medication. Persistent limited weight response despite an adequate trial is more relevant than one particular sensation.

Should I take a higher GLP-1 dose if it isn’t working?

Only under prescriber guidance. Current guidelines support dose optimization when appropriate, but titration must also consider tolerability. FDA has received reports of serious adverse events associated with compounded semaglutide and tirzepatide products involving dosing mistakes or doses beyond approved labeling.

Can GLP-1 medications simply not work for some people?

Yes. Treatment response is heterogeneous, and a minority of patients experience inadequate weight reduction despite treatment. Researchers do not yet have a validated baseline biomarker that reliably identifies these patients before treatment.

What comes after GLP-1 treatment if medication still doesn’t achieve my goals?

Depending on the individual, clinicians may consider a different obesity medication, more intensive structured lifestyle treatment, combination pharmacotherapy, obesity-specialist referral or metabolic/bariatric surgery. These options have different evidence, eligibility requirements, risks and costs and should be selected through clinical evaluation rather than self-treatment.